Advertisement
Advertisement
UTHR
United Therapeutics Corp
554.73
USDSponsored
-4.37
-0.78%
Nov 20, 15:59 UTC -5
Closed
After-Market
550.29
-4.44
-0.80%
United Therapeutics Corp (UTHR) Earnings
UTHR Earnings Reports
Positive Surprise Ratio
UTHR beat 22 of 44 last estimates.
50%
Next Report
Date of Next Report
Feb 23, 2027
Estimate for Q4 26 (Revenue/ EPS)
$883.41M
/$6.81
Implied change from Q3 26 (Revenue/ EPS)
+6.11%
/+19.26%
Implied change from Q4 25 (Revenue/ EPS)
+11.80%
/-11.56%
United Therapeutics Corp earnings per share and revenue
On Nov 04, 2026, UTHR reported earnings of 5.71 USD per share (EPS) for Q3 26, missing the estimate of 6.55 USD, resulting in a -12.86% surprise. Revenue reached 832.50 million, compared to an expected 796.84 million, with a 4.47% difference. The market reacted with a +1.19% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 8 analysts forecast an EPS of 6.81 USD, with revenue projected to reach 883.41 million USD, implying an increase of 19.26% EPS, and increase of 6.11% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%

Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%

Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%

Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%

NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%

Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%

Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%

Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%

Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%

60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
What were United Therapeutics Corp's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, United Therapeutics Corp reported EPS of $5.71, missing estimates by -12.86%, and revenue of $832.50M, 4.47% above expectations.
How did the market react to United Therapeutics Corp's Q3 2026 earnings?
The stock price moved up 1.19%, changed from $601.32 before the earnings release to $608.49 the day after.
When is United Therapeutics Corp expected to report next?
The next earning report is scheduled for Feb 23, 2027.
What are the forecasts for United Therapeutics Corp's next earnings report?
Based on 8
analysts, United Therapeutics Corp is expected to report EPS of $6.81 and revenue of $883.41M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.